Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Chen, Wei Prof. Dr. (1) Fritsche, Raphaela Dr. (1) Kempa, Stefan Dr. (10) Landthaler, Markus Prof. Dr. (1) Schmidt-Krüger, Vanessa Dr. (1) Willnow, Thomas Prof. Dr. (1) (-) Blüthgen, Nils (1) (-) Mastrobuoni, Guido Dr. (2) 2011 (4) 2012 (2) (-) 2014 (1) 2015 (4) (-) 2016 (2) 2017 (2) 2018 (2) 2019 (2) 2022 (2) 2023 (2) 2024 (1) AG Müller/Dechend (ECRC) (1) Biology of Malignant Lymphomas (5) Experimental Ultrahigh-Field MR (8) Genome Engineering & Disease Models (1) Hypertension-caused End-Organ Damage (1) Hypertension-Mediated End-Organ Damage (1) Immune Regulation and Cancer (3) Magnetic Resonance (8) (-) Proteomics and Metabolomics (3) RNA Biology and Posttranscriptional Regulation (1) Transgenics (1) Translational Oncology of Solid Tumors (1) 3 Results: Active Filter: Blüthgen, NilsMastrobuoni, Guido Dr.Proteomics and Metabolomics20142016 Sort: Result score Newest to oldest Oldest to newest May 22, 2014 / Mol Cell MOV10 is a 5' to 3' RNA helicase contributing to UPF1 mRNA target degradation by translocation along 3' UTRs L.H. Gregersen M. Schueler M. Munschauer G. Mastrobuoni W. Chen S. Kempa C. Dieterich M. Landthaler March 04, 2016 / J Proteome Res Proteomics quality control : a quality control software for MaxQuant results C. Bielow G. Mastrobuoni S. Kempa January 20, 2016 / Oncotarget Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis R. Fritsche-Guenther F. Witzel S. Kempa T. Brummer C. Sers N. Blüthgen
May 22, 2014 / Mol Cell MOV10 is a 5' to 3' RNA helicase contributing to UPF1 mRNA target degradation by translocation along 3' UTRs L.H. Gregersen M. Schueler M. Munschauer G. Mastrobuoni W. Chen S. Kempa C. Dieterich M. Landthaler
March 04, 2016 / J Proteome Res Proteomics quality control : a quality control software for MaxQuant results C. Bielow G. Mastrobuoni S. Kempa
January 20, 2016 / Oncotarget Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis R. Fritsche-Guenther F. Witzel S. Kempa T. Brummer C. Sers N. Blüthgen